MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.22 Million EUR | 55.8% |
| 2022 | 1.43 Million EUR | 47.12% |
| 2021 | 972 Thousand EUR | 0.0% |
| 2020 | - EUR | -100.0% |
| 2019 | 89.3 Thousand EUR | -89.99% |
| 2018 | 892 Thousand EUR | 715.95% |
| 2017 | 109.32 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 860.5 Thousand EUR | 102.47% |
| 2024 Q2 | 860.5 Thousand EUR | 100.0% |
| 2023 Q1 | 689 Thousand EUR | -26.39% |
| 2023 Q2 | 1.37 Million EUR | 100.0% |
| 2023 FY | 2.22 Million EUR | 55.8% |
| 2023 Q3 | 425 Thousand EUR | -69.16% |
| 2023 Q4 | 425 Thousand EUR | 0.0% |
| 2022 FY | 1.43 Million EUR | 47.12% |
| 2022 Q4 | 936 Thousand EUR | 100.0% |
| 2022 Q3 | 468 Thousand EUR | -5.26% |
| 2022 Q2 | 494 Thousand EUR | 100.0% |
| 2022 Q1 | 247 Thousand EUR | -57.92% |
| 2021 Q4 | 587 Thousand EUR | 100.0% |
| 2021 FY | 972 Thousand EUR | 0.0% |
| 2021 Q3 | 293.5 Thousand EUR | -23.77% |
| 2021 Q2 | 385 Thousand EUR | 100.0% |
| 2021 Q1 | 192.5 Thousand EUR | 133.89% |
| 2020 FY | - EUR | -100.0% |
| 2020 Q3 | -568 Thousand EUR | -200.0% |
| 2020 Q2 | 568 Thousand EUR | 0.0% |
| 2020 Q1 | 568 Thousand EUR | 0.0% |
| 2020 Q4 | -568 Thousand EUR | 0.0% |
| 2019 FY | 89.3 Thousand EUR | -89.99% |
| 2018 FY | 892 Thousand EUR | 715.95% |
| 2017 FY | 109.32 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 51.983% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 51.785% |
| Adocia SA | 2.15 Million EUR | -3.628% |
| Aelis Farma SA | 9.05 Million EUR | 75.392% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 29.292% |
| genOway Société anonyme | 20.04 Million EUR | 88.886% |
| IntegraGen SA | 12.53 Million EUR | 82.229% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -642.583% |
| Neovacs S.A. | 533.41 Thousand EUR | -317.688% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -32.5% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -11154.799% |
| Sensorion SA | 4.74 Million EUR | 53.026% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -651.862% |
| TME Pharma N.V. | 17 Thousand EUR | -13005.882% |
| Valbiotis SA | 4.73 Million EUR | 52.926% |
| TheraVet SA | 1.07 Million EUR | -106.668% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -23.778% |
| argenx SE | 1.13 Billion EUR | 99.804% |
| BioSenic S.A. | 543 Thousand EUR | -310.313% |
| Celyad Oncology SA | 102 Thousand EUR | -2084.314% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.071% |
| Genfit S.A. | 28.56 Million EUR | 92.2% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -6.756% |
| Innate Pharma S.A. | 51.9 Million EUR | 95.707% |
| Inventiva S.A. | 17.47 Million EUR | 87.252% |
| MedinCell S.A. | 9.16 Million EUR | 75.677% |
| Nanobiotix S.A. | 30.05 Million EUR | 92.588% |
| Onward Medical N.V. | 532 Thousand EUR | -318.797% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 84.301% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -0.045% |
| Oxurion NV | 263 Thousand EUR | -747.148% |
| Pharming Group N.V. | 245.31 Million EUR | 99.092% |
| Poxel S.A. | 1.98 Million EUR | -12.468% |
| GenSight Biologics S.A. | 1.26 Million EUR | -75.848% |
| Transgene SA | 1.18 Million EUR | -88.176% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.958% |
| Valneva SE | 153.71 Million EUR | 98.551% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 161.547% |